Search
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalIn contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedIt achieves high overall accuracy in detecting SLN [A32169]. … Once reconstituted and labelled, technetium Tc99m tilmanocept is intended to be injected in close proximity to the tumor being diagnosed and employed in preoperative gamma detection imaging in combination
Tradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigational[L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363] … [L54903] NK-1 receptors are expressed in the brainstem and nucleus tractus solitarius, which receives emetogenic signals from various stimuli including dizziness and vertigo.
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic
Diethylcarbamazine
go.drugbank.com/drugs/DB00711ApprovedInvestigationalVet approvedWithdrawnAn anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnIt was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three … Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class.
Influenza A virus A/Singapore/GP1908/2015 IVR-180 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14462ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019Influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14463ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019